Evidence map›Paper›PMID 34633875›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Iron Chelation Reduces DNA Damage in Sickle Cell Anemia.

Rawan S Al-Khateeb, Hanan S Althagafy, Mohammad Zaki ElAssouli, Dunya A Nori, Mohammed AlFattani, Salwa A Al-Najjar, Turki Al Amri, Anwar M Hashem, Steve Harakeh, Nawal Helmi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Rawan S Al-Khateeb37848Department of Biochemistry, King Abdulaziz University, Jeddah, Saudi Arabia, KSA.
Hanan S Althagafy441424Department of Biochemistry, University of Jeddah, Jeddah, KSA.
Mohammad Zaki ElAssouli37848Vaccines and Immunotherapy Unit, King Fahd Medical Research Center (KFMRC); Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, KSA.
Dunya A Nori37848Department of Biochemistry, King Abdulaziz University, Jeddah, Saudi Arabia, KSA.
Mohammed AlFattani294798Maternity and Children Hospital, Jeddah, KSA.
Salwa A Al-Najjar37848Department of Hematology, King Abdulaziz University, KSA.
Turki Al Amri37848Family and Community Medicine Department, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0003-4382-4109
Anwar M Hashem37848Vaccines and Immunotherapy Unit, King Fahd Medical Research Center (KFMRC); Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, KSA.
Steve Harakeh37848Special Infectious Agents Unit, and Yousef Abdullatif Jameel Chair of Prophetic Medicine Application, Faculty of Medicine, King Abdulaziz University, KSA.
Nawal Helmi441424Department of Biochemistry, University of Jeddah, Jeddah, KSA.
King Abdulaziz University · SAUniversity of Jeddah · SAMaternity and Children's Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sickle cell anemia (SCA) is a blood condition that causes severe pain. One of the therapeutic agents used for the treatment of SCA is hydroxyurea, which reduces the episodes of pain but causes DNA damage to white blood cells. The aim of this study was to evaluate the efficacy of the combination of hydroxyurea and iron chelation therapy in relation to the extent of DNA-associated damage. Blood samples were collected from 120 subjects from five groups. Various hematological parameters of the obtained serum were analyzed. The amount of damage caused to their DNA was detected using the comet assay and fluorescent microscopy techniques. The percentage of DNA damage in the group that was subjected to the combination therapy (target group) was 1.32% ± 1.51%, which was significantly lower (

Indexed as

AdolescentAdultAnemia, Sickle CellChildDNA DamageFemaleHumansIron Chelating AgentsMaleYoung AdultIron Chelating AgentsDNA damagehydroxyureairon chelation therapyleukocyte DNAsickle cell anemia

Identifiers

PMID34633875
PMCPMC8521763
OpenAlexW3205020605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.